Halifax, Canada Clinical Trials

A listing of Halifax, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 75 clinical trials
Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke

The proposed trial is a pragmatic, registry based, prospective, randomized (1:1) controlled, open-label parallel group clinical trial with blinded endpoint assessment of 1600 patients to test if intravenous tenecteplase (0.25 mg/kg body weight, max dose 25 mg) is non-inferior to intravenous alteplase (0.9 mg/kg body weight) in patients with acute …

plasminogen activator
tissue plasminogen activator
ischemic stroke
Queen Elizabeth Hospital
 (111.5 away) Contact site
  • 19 Sep, 2021
  • +23 other locations
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer. The primary hypotheses are: The combination of NUC-1031 plus cisplatin prolongs overall survival compared to the gemcitabine plus cisplatin standard of care The combination of NUC-1031 plus cisplatin increases overall response …

advanced biliary tract carcinoma
platelet count
measurable disease
international normalized ratio
Nova Scotia Health Authority
 (0.7 away) Contact site
  • 19 Sep, 2021
  • +129 other locations
Hospital-Based Cluster Trial: Magnetically Controlled Growing Rods Using Distraction Intervals

A hospital-based cluster stratified randomization control study will be conducted to investigate spinal growth in Early Onset Scoliosis patients between 5 and 9 years of age. Patients must have a major coronal curve measuring over 50 degrees and be undergoing Magnetically Controlled Growing Rod treatment. We will be studying 6-week …

IWK Health Centre
 (1.4 away) Contact site
  • 19 Sep, 2021
  • +21 other locations
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL Mixed Phenotype Acute Leukemia and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab …

chemotherapy regimen
b-cell acute lymphoblastic leukemia
cancer chemotherapy
IWK Health Centre
 (1.4 away) Contact site
  • 12 Sep, 2021
  • +113 other locations
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (300/L). Eligible patients must have a history of 2 moderate and/or severe COPD exacerbations in the previous year …

eosinophil count
severe chronic obstructive pulmonary disease
Research Site
 (0.6 away) Contact site
  • 10 Sep, 2021
  • +438 other locations
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

Major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR rate of pembrolizumab as a single agent. Additionally the dynamics of the tumor microenvironment changes on treatment by comparing pre-, on- and post-treatment …

Novartis Investigative Site
 (0.8 away) Contact site
  • 19 Sep, 2021
  • +44 other locations
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement …

hepatic fibrosis
Nova Scotia Health Authority QEII (Queen Elizabeth II) Health Sciences Centre
 (0.8 away) Contact site
  • 08 Sep, 2021
  • +350 other locations
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Patients will be randomly assigned to …

b-cell lymphoma
measurable disease
Queen Elizabeth II Health Sciences Centre
 (0.7 away) Contact site
  • 19 Sep, 2021
  • +79 other locations
A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants.

lower respiratory tract infection
Canadian Center for Vaccinology - IWK Health Centre
 (1.4 away) Contact site
  • 19 Sep, 2021
  • +463 other locations
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein …

IWK Health Centre
 (0.2 away) Contact site
  • 12 Sep, 2021
  • +115 other locations